ClinicalTrials.gg
RecruitingNCT06097949Updated Oct 24, 2023

AcuPebble to Remotely Monitor Patients With OSA on CPAP Therapy

An observational study in Sleep Apnea, Obstructive, sponsored by Royal Free Hospital NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Royal Free Hospital NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom — 9 open to participants now, 13 under way, none of them phase 3. Sleep Apnea, Obstructive · United Kingdom.

Planned enrollment
25th of 28
25 · median 102
Started
2022
with 4 others
Observational
28 of 54
6 open now
Primary completion
2024-02
later than 1 of 12 live
Registered
44th of 54
by date
Lead sponsor
2 of 54
Royal Free Hospital NHS Foundation Trust

Among the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, this one is the 25th largest by planned enrollment of the 28 observational ones that give a count, is one of 5 that started in 2022, is one of 28 observational ones, reaches primary completion later than 1 of the 12 other live ones, and was the 44th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

9 of the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, or all of them as a file.
02

Study summary

Obstructive sleep apnoea (OSA) is a breathing problem that happens when you sleep. It is treated by a machine called continuous positive airway pressure (CPAP) therapy.

The goal of this observational trial is to test how well a new wearable device can detect ongoing OSA in patients undergoing treatment with CPAP. The main questions it aims to answer are:

  1. Does the new wearable device detect OSA in patients undergoing treatment with CPAP as well as gold standard sleep studies?
  2. Does the new wearable device detect OSA in patients undergoing treatment with CPAP more accurately than the CPAP machine can itself.

Participants will be asked to wear the following two devices while using their CPAP machine for 2 nights:

  1. AcuPebble SA100 (the new wearable device). This device is the size of a 2-pence coin and sits on the front of the neck and attaches via some double sided sticky tape. It is connected via bluetooth to a mobile phone application (app).
  2. A multi-channel sleep study, which is the gold standard way of performing sleep studies.

Researchers will then compare how much OSA is left in participants, comparing the values from the new device, gold standard sleep study and the CPAP machine itself.

Read the detailed description

Obstructive sleep apnoea (OSA) affects almost one billion people globally and can lead to numerous health consequences including ischaemic heart disease, hypertension, stroke and arrhythmias. It also has a profound impact on patient's quality of life and has a high economic burden on society. Continuous positive airway pressure (CPAP) therapy is globally accepted gold-standard treatment, virtually eliminating OSA (by normalising the apnoea-hypopnoea index (AHI)), thus improving quality of life, decreasing sleepiness and reducing medical sequelae. A high residual AHI may still be present despite adequate CPAP usage in some patients. This patient population will suffer with on-going / worsening somnolence, sleep apnoea symptoms and potentially increased cardiovascular risk, which will no doubt reduce their adherence thus increasing their residual AHI, perpetuating a viscous cycle.

Currently CPAP machines can store airflow and pressure data, displaying residual events and compliance indices. However, algorithms between devices vary and there are no standards on how to use the data, and there is mixed data surrounding residual event accuracy. A review by the American Thoracic Society concluded that while CPAP usage can be reliably determined from tracking systems, residual events (residual AHI) and mask leak data are not easy to interpret and differ depending on manufactures. Some studies have found that this is especially the case in relation to detecting hypopnoeic events. Therefore, a more accurate and simple system is needed to accurately determine usage and residual events, that is: standardised, reliable and independent of machine manufacturer. Overnight oximetry is used by some Trusts as a surrogate marker of residual events. However, studies that have validated overnight oximetry against polysomnography (gold standard) have found the specificity and sensitivity decrease with decreasing severity of disease. Therefore this is not a practical or reliable way to monitor patients remotely.

Therefore we aim to assess whether we can accurately measure the residual AHI with a simple, accurate, novel wearable device in patients undergoing CPAP therapy. This will enable us to accurately assess treatment effect and highlight patients who require more intensive / change in their therapy.

AcuPebble SA100 is a CE marked novel wearable device developed by Acurable Ltd which has already been validated as an automated diagnostic tool for OSA with a high positive (96%) and high negative (995) predictive value when compared to a gold standard sleep study. This is currently in clinical use. We intend to assess whether AcuPebble SA100 can also be used to accurately detect the residual AHI in patients with OSA on CPAP therapy.

Patients in this study will be asked to wear both AcuPebble SA100 and a gold standard multi-channel sleep study simultaneously, alongside using CPAP therapy for two consecutive nights. We will then compare the residual AHI from AcuPebble SA100 with gold standard, as well as comparing the accuracy of the CPAP machine AHI with gold standard. This will also enable us to detect whether AcuPebble SA100 is more accurate that the CPAP machine.

We will also assess the usability of AcuPebble SA100 in this population.

03

Conditions studied

  • Sleep Apnea, Obstructive

Keywords

  • OSA
  • CPAP
  • Wearable technology
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with an existing diagnosis of obstructive sleep apnoea who have been established on continuous positive airway pressure (CPAP) therapy and are deemed compliant with therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with an initial diagnosis of moderate/severe OSA (AHI ≥ 15events/hr made on full polysomnography, cardiorespiratory-polygraphy or other validated home sleep study) with no evidence of hypoventilation
  2. Patients who have been established on CPAP therapy for > 3months
  3. Patients who are deemed compliant on CPAP therapy (average use ≥ 4 hours/night for ≥ 70% of the last 28 days)

Exclusion criteria

Exclusion Criteria:

  • Age \<18
  • Subjects not fluent in English, or who have special communication needs
  • Known allergy to adhesive dressing
  • Subjects with physical or mental impairments who would not be able to use the device and technology on their own
  • Subjects with implantable devices
  • Subjects with stridor
  • Subjects unable to give consent
  • Subjects on non-invasive ventilation (NIV) or bi-level positive airway pressure (BIPAP)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No

Interventions

  • DeviceAcuPebble SA100

    This device is not being used as an interventional device but simply a monitoring tool on patients already on CPAP therapy. The device is being used within the scope of it's intended purpose as a medical device to diagnose OSA.

06

What researchers measure

Primary outcomes

  1. Accuracy of the residual AHI measured by AcuPebble SA100

    Our primary outcome will be to measure the residual AHI with AcuPebble SA100 and compare the accuracy of this measurement against a gold standard multi-channel sleep study. The residual AHI is a measurement that quantifies the amount of sleep disordered breathing that is still present despite treatment.

    Time frame: 6 months

Secondary outcomes

  1. Comparing the residual AHI measured by AcuPebble SA100 and the CPAP machine

    To measure the residual AHI with AcuPebble SA100 and compare it to the measurement dervied from the continuous positive airway pressure (CPAP) machine. The residual AHI is a measurement that quantifies the amount of sleep disordered breathing that is still present despite treatment.

    Time frame: 6 months

  2. Accuracy of the effective AHI measured by AcuPebble SA100

    To measure the total night-time AHI (effective AHI) using AcuPebble SA100 and compare this measurement to a gold standard multi-channel sleep study. The residual AHI is a measurement that quantifies the amount of sleep disordered breathing that is still present despite treatment.

    Time frame: 6 months

  3. Measure the acceptability of AcuPebble SA100

    To measure how comfortable AcuPebble SA100 is to wear for people while they use their CPAP machine.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Academic Respiratory Department Royal Free Hospital NHS Foundation Trust
    London, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan to share individual participant data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Feb 2024, 16 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 16 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Oct 24, 2023
StartActual
Oct 7, 2022
Primary completionEst.
Feb 2024
CompletionEst.
Feb 2024
Last update
Oct 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06097949
Lead sponsor
Royal Free Hospital NHS Foundation Trust
Collaborators
Acurable Ltd.
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Oct 7, 2022
Primary completion
Feb 2024 (estimated)
Completion
Feb 2024 (estimated)
Last update
Oct 24, 2023

Study contacts

Swapna Mandal, PhD
Contact
swapnamandal@nhs.net
0207 794 0500 ext. 23359
R&D Manager
Contact
rf.randd@nhs.net
02077940500

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion